Zacks Investment Research·1d ago
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
Merck's near-term earnings are being distorted by a deliberate R&D surge, with spending tripling to $12.6B in 2026Q1 and driving operating losses, yet the company maintains a stable top line with 5.1% revenue growth in 2026Q2.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth is stable at 5.1% in 2026Q2, but operating margins have swung from a 43.4% profit in 2025Q3 to a -4.1% loss in 2026Q2 due to R&D spending surging to $12.6B in 2026Q1.
Merck has achieved an annual earnings growth of 16.8% over the last five years, outpacing revenue growth.
Management projects over $70 billion in commercial opportunities by the mid-2030s, with key drugs like Welireg showing strong growth.
Merck's P/E ratio stands at 14.8x, below the industry average, and offers a dividend yield of 3.11%.
Keytruda accounts for roughly half of Merck's revenue, raising concerns about earnings impact post-2028 patent loss.
Some DCF analyses suggest fair value prices significantly lower than the current trading price, indicating possible overvaluation.
Recent technical analysis shows bearish signals, including a 10-day moving average crossing below the 50-day moving average.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $2.49+19.1% vs $2.09 | $18.1B+4.4% vs $17.3B |
Q3 2026 Aug 4, 2026 | -$0.13+51.9% vs -$0.27 | $16.6B+1.5% vs $16.4B |
Q2 2026 Apr 30, 2026 | -$1.28+12.9% vs -$1.47 | $16.3B+2.8% vs $15.8B |
Q1 2026 Feb 3, 2026 | $2.04+1.5% vs $2.01 | $16.4B+1.2% vs $16.2B |
MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
Compass Financial Management LLC lifted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 256.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,733 shares of the company's stock after purchasing an additional 7,001 shares during the quarter.
Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.
Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 393,390 shares of the company's stock after selling 53,672 shares during the period. Boston Trust Walden
Benchmark MRK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Merck & Co., Inc. (MRK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $146.71 | $362.35B | 20.15 | 1.18% | 28.12% | 36.86% | 2.22% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% | |
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.9% | 83.64% | 0.44% | |
| $291.31 | $514.68B | 122.92 | 8.57% | 15.68% | 286.66% | 2.26% | |
| $62.14 | $126.89B | 18.01 | -0.22% | 18.47% | 43.84% | 3.98% | |
| $460.42 | $248.49B | 32.36 | 9.92% | 24.12% | 85.59% | 2.05% |
Merck & Co., Inc. (MRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Merck & Co., Inc. (MRK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 28, 2026·SEC
May 22, 2026·SEC
Get notified when MRK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Merck & Co., Inc. (MRK) stock FAQ — growth, dividends, profitability & financials explained
Merck & Co., Inc. (MRK) reported $66.40B in revenue over the trailing twelve months. Revenue was $64.93B in fiscal year 2025. That is 227% more than the $19.83B of fiscal year 1996.
Merck & Co., Inc. (MRK) grew revenue by 1.2% in fiscal year 2025, compared with the prior fiscal year.
Yes. Merck & Co., Inc. (MRK) earned $3.17B in net income over the trailing twelve months (a 4.8% net margin).
Yes. Merck & Co., Inc. (MRK) pays a dividend that yields 2.22% at the current price, a moderate yield.
Merck & Co., Inc. (MRK) had a return on equity (ROE) of 36.9% in fiscal year 2025. That is well above the market's typical 10-15%.
Merck & Co., Inc. (MRK) generated $16.06B in free cash flow over the trailing twelve months.
